Ensysce Biosciences Announces $15 Million Convertible Note Financing
SAN DIEGO, SEPTEMBER 27, 2021 - Ensysce Biosciences, Inc. , a clinical-stage biotech company with... | September 27, 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech
SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech...
Ensysce Biosciences
is the latest local company to join the public market after closing the merger deal on July 1. The company will be trading its common stock...
SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ENSC ("Ensysce" or "the Company"), a clinical stage biotech company with proprietary
SAN DIEGO, July 01, 2021 -- Ensysce Biosciences, Inc. today announced that the Company will begin trading its common stock under the ticker symbol “ENSC” on The Nasdaq Capital...
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW) today announced that the Company
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC: LACQ, LACQW) today announced that, in connection with